Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the efficacy of olanzapine as compared to
neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea
and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient
chemotherapy (carboplatin and paclitaxel) every 3 weeks.